Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scynexis has earned a fourth payment for meeting certain milestones in a multi-year research collaboration which began in 2005 with Merial Limited.
Subscribe to our email newsletter
Scynexis, a drug discovery and development company, directs medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial’s animal health discovery efforts.
Scynexis president and CEO Yves Ribeill said that the company is pleased to earn another important research milestone through their valued partnership with Merial.
"This is the fourth consecutive milestone we have reached for delivering significant, innovative animal health development candidates to Merial under the agreement," Ribeill said.
Merial Discovery and Research head Christian Miculka said that Merial is delighted to see this latest success resulting from the pharmaceutical discovery collaboration with Scynexis.